Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC trimmed its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 276,647 shares of the biopharmaceutical company’s stock after selling 5,427 shares during the quarter. Moody Aldrich Partners LLC owned about 0.23% of Catalyst Pharmaceuticals worth $5,500,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC increased its position in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 681 shares during the period. nVerses Capital LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $50,000. CWM LLC increased its position in Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 3,549 shares during the period. Meeder Asset Management Inc. acquired a new stake in Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $70,000. Finally, SG Americas Securities LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $173,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX traded up $0.04 during trading on Thursday, reaching $21.38. The stock had a trading volume of 64,001 shares, compared to its average volume of 1,200,396. Catalyst Pharmaceuticals, Inc. has a 52 week low of $11.89 and a 52 week high of $21.85. The business’s 50-day moving average price is $20.31 and its 200 day moving average price is $17.53. The stock has a market capitalization of $2.53 billion, a PE ratio of 39.52, a P/E/G ratio of 3.18 and a beta of 0.76.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. The company had revenue of $122.71 million during the quarter, compared to analysts’ expectations of $111.76 million. Analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current year.

Insider Buying and Selling

In other news, insider Steve Miller sold 150,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the transaction, the insider now owns 675,124 shares of the company’s stock, valued at $13,738,773.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the transaction, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the transaction, the insider now directly owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 201,058 shares of company stock worth $4,018,188 in the last quarter. Insiders own 11.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CPRX shares. HC Wainwright increased their price target on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Citigroup raised their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Truist Financial raised their target price on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $29.50.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.